GE HealthCare Advances Novel Mangaciclanol MRI Contrast Agent into Phase 2/3 LUMINA Trial

GE HealthCare has announced that the first patient has been dosed in the Phase 2/3 LUMINA clinical trial evaluating mangaciclanol, a breakthrough manganese-based MRI contrast agent.

The international multi-centre study began at Mayo Clinic in Rochester, Minnesota, and marks a major step in the company’s imaging innovation pipeline.

Mangaciclanol is being developed as a potential alternative to gadolinium-based MRI contrast agents, which are currently widely used in diagnostic imaging. 

The investigational agent has received Fast Track designation from the US Food and Drug Administration for use in adults and children aged two years and above to help detect and visualise lesions in the central nervous system and other parts of the body.

MRI contrast agents are used to improve the visibility of abnormal tissues and lesions during scans. According to the company, mangaciclanol has shown imaging performance comparable to gadolinium-based agents in early studies. 

Unlike gadolinium, manganese is a naturally occurring element found in food and water, which may help reduce concerns linked to metal retention and environmental impact.

Phase 1 clinical results showed that mangaciclanol was well tolerated, with no serious adverse events or clinically significant findings reported. 

The investigational agent is currently under clinical development and has not yet received regulatory approval for commercial use.